MediWound reports Q3 EPS (24c), consensus (98c)

Reports Q3 revenue $5.429M, consensus $6.56M. “We continued to execute our growth strategy this quarter, advancing both our operational capabilities and our late-stage clinical programs,” said Ofer Gonen, Chief Executive Officer of MediWound (MDWD). “Completion of commissioning for our expanded NexoBrid manufacturing facility marks a significant milestone that positions us to meet rising global demand. Enrollment in the VALUE Phase III trial of EscharEx is progressing under a robust study design aligned with endpoints where EscharEx demonstrated strong results in Phase II. With a strengthened balance sheet following our recent $30 million equity financing, we remain focused on driving revenue growth, advancing our late-stage pipeline, and delivering long-term value.”